Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for CRNX
| Stock Name | Crinetics Pharmaceuticals Inc |
| Ticker | CRNX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US22663K1079 |
| LEI | 549300Q1CNFXK5P31D28 |
Show aggregate CRNX holdings
News associated with CRNX
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $68.86 Consensus Price Target from Brokerages
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective […] - 2025-08-19 02:16:54
- Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $86.00 by Analysts at JMP Securities
- Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price reduced by JMP Securities from $90.00 to $86.00 in a report published on Monday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research firms have also recently weighed in on CRNX. HC Wainwright reaffirmed a “buy” rating and set […] - 2025-08-12 04:47:05
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.
- Victory Capital Management Inc. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,331 shares of the company’s stock after selling 30,120 shares during the quarter. Victory Capital Management Inc.’s holdings in […] - 2025-07-25 06:06:53
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price […] - 2025-07-22 07:55:07
- New York State Common Retirement Fund Sells 17,508 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- New York State Common Retirement Fund lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,918 shares of the company’s stock after selling 17,508 shares during the quarter. New York State Common […] - 2025-07-22 07:13:05
- Teacher Retirement System of Texas Decreases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Teacher Retirement System of Texas decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 6.5% in the 1st quarter, Holdings Channel reports. The fund owned 22,442 shares of the company’s stock after selling 1,561 shares during the quarter. Teacher Retirement System of Texas’ holdings in Crinetics Pharmaceuticals were worth $753,000 […] - 2025-07-15 04:24:35
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Moderate Buy” from Brokerages
- Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year […] - 2025-07-02 04:30:55
- Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $3,141,877.09 in Stock
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Stephen F. Betz sold 97,483 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the transaction, the insider now owns 99,713 shares of the company’s stock, valued […] - 2025-06-19 05:10:52
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Mackenzie Financial Corp
- Mackenzie Financial Corp grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,422 shares of the company’s stock after purchasing an additional 440 shares during the period. Mackenzie Financial Corp’s holdings […] - 2025-06-05 06:18:55
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Brokerages
- Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 […] - 2025-06-02 02:10:52
- State of Wyoming Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- State of Wyoming purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 985 shares of the company’s stock, valued at approximately $50,000. Several other large investors […] - 2025-05-30 05:06:48
- Bank of America Corp DE Cuts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Bank of America Corp DE decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 15.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 235,281 shares of the company’s stock after selling 42,792 shares during the period. Bank of America Corp DE’s holdings in Crinetics Pharmaceuticals were worth $12,030,000 […] - 2025-05-23 06:26:56
- BNP Paribas Financial Markets Sells 5,683 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- BNP Paribas Financial Markets decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 27.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,259 shares of the company’s stock after selling 5,683 shares during the period. BNP Paribas Financial Markets’ holdings in Crinetics Pharmaceuticals were worth $780,000 at the […] - 2025-05-23 04:58:51
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 6,719 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,163 shares of the company’s stock after acquiring an additional 6,719 shares during […] - 2025-05-21 05:40:53
- Ameriprise Financial Inc. Has $18.16 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Ameriprise Financial Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 110.8% during the fourth quarter, Holdings Channel reports. The fund owned 355,174 shares of the company’s stock after buying an additional 186,681 shares during the quarter. Ameriprise Financial Inc.’s holdings in Crinetics Pharmaceuticals were worth $18,159,000 as of […] - 2025-05-16 05:03:19
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Analysts
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target […] - 2025-05-08 02:22:53
- Envestnet Asset Management Inc. Buys 8,751 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Envestnet Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.1% during the 4th quarter, HoldingsChannel reports. The fund owned 63,077 shares of the company’s stock after buying an additional 8,751 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Crinetics Pharmaceuticals were worth $3,225,000 as […] - 2025-04-25 04:24:46
- Legal & General Group Plc Buys 12,538 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Legal & General Group Plc lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 88,939 shares of the company’s stock after acquiring an additional 12,538 shares during the quarter. Legal & General Group Plc’s holdings in Crinetics Pharmaceuticals were worth $4,547,000 as […] - 2025-04-22 04:47:14
- Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer
- Representative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account. Representative Josh […] - 2025-04-14 03:02:59
- Corebridge Financial Inc. Buys 1,992 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Corebridge Financial Inc. boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,599 shares of the company’s stock after buying an additional 1,992 shares during the period. Corebridge Financial Inc.’s holdings […] - 2025-04-02 06:46:52
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.
- Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company’s stock after acquiring an additional 2,801,736 shares during the quarter. Vanguard Group […] - 2025-04-02 05:24:53
- 16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning AS
- KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company’s stock, valued at approximately $818,000. A number of other hedge funds have also added to […] - 2025-04-01 05:14:54
- Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel Nicolaus
- Analysts at Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 73.86% from the stock’s previous close. […] - 2025-03-27 04:00:59
- Arizona State Retirement System Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Arizona State Retirement System boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,469 shares of the company’s stock after purchasing an additional 4,168 shares during the […] - 2025-03-14 06:10:48
- Assetmark Inc. Purchases 1,014 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Assetmark Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,161 shares of the company’s stock after acquiring an additional 1,014 shares during the quarter. Assetmark Inc.’s holdings in Crinetics Pharmaceuticals […] - 2025-03-12 06:11:03
- Keybank National Association OH Has $478,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Keybank National Association OH boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 9,352 shares of the company’s stock after purchasing an additional 1,176 shares during the quarter. Keybank National Association OH’s holdings in Crinetics Pharmaceuticals were worth $478,000 at […] - 2025-03-10 05:54:54
- Handelsbanken Fonder AB Buys 2,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- Handelsbanken Fonder AB raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Crinetics Pharmaceuticals were worth $1,115,000 at the end […] - 2025-02-28 07:25:04
- New York State Common Retirement Fund Purchases 7,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
- New York State Common Retirement Fund lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 155,426 shares of the company’s stock after purchasing an additional 7,735 shares during the quarter. New York State Common Retirement Fund’s holdings in Crinetics […] - 2025-02-27 06:51:01
- Add Up The Pieces: VBK Could Be Worth $335
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-02-13 13:24:24
- TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)
- Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […] - 2025-02-13 08:26:44
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) CRNX holdings
| Date | Number of CRNX Shares Held | Base Market Value of CRNX Shares | Local Market Value of CRNX Shares | Change in CRNX Shares Held | Change in CRNX Base Value | Current Price per CRNX Share Held | Previous Price per CRNX Share Held |
|---|
| 2026-02-09 (Monday) | 69,301 | USD 3,188,539 | USD 3,188,539 | | | | |
| 2026-02-06 (Friday) | 69,147 | USD 3,130,976 | USD 3,130,976 | 154 | USD -273,829 | USD 45.28 | USD 49.35 |
| 2026-02-02 (Monday) | 68,993 | USD 3,404,805 | USD 3,404,805 | 0 | USD -40,705 | USD 49.35 | USD 49.94 |
| 2026-01-30 (Friday) | 68,993 | USD 3,445,510 | USD 3,445,510 | 308 | USD -117,868 | USD 49.94 | USD 51.88 |
| 2026-01-29 (Thursday) | 68,685 | USD 3,563,378 | USD 3,563,378 | 154 | USD -66,366 | USD 51.88 | USD 52.965 |
| 2026-01-27 (Tuesday) | 68,531 | USD 3,629,744 | USD 3,629,744 | 154 | USD 38,584 | USD 52.965 | USD 52.52 |
| 2026-01-26 (Monday) | 68,377 | USD 3,591,160 | USD 3,591,160 | 0 | USD -45,129 | USD 52.52 | USD 53.18 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of CRNX by Blackrock for IE00BYXG2H39
Show aggregate share trades of CRNX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2026-02-06 | BUY | 154 | | | 45.280* | | - |
| 2026-01-30 | BUY | 308 | 52.950 | 49.310 | 49.674 | USD 15,300 | - |
| 2026-01-29 | BUY | 154 | 52.615 | 50.970 | 51.135 | USD 7,875 | - |
| 2026-01-27 | BUY | 154 | 53.270 | 51.765 | 51.915 | USD 7,995 | - |
| 2026-01-23 | BUY | 308 | 55.270 | 52.940 | 53.173 | USD 16,377 | - |
| 2026-01-22 | BUY | 154 | 56.700 | 54.090 | 54.351 | USD 8,370 | - |
| 2026-01-16 | BUY | 2,852 | 56.855 | 55.480 | 55.617 | USD 158,621 | - |
| 2026-01-15 | BUY | 296 | 56.550 | 53.705 | 53.990 | USD 15,981 | - |
| 2026-01-14 | BUY | 296 | 56.070 | 53.450 | 53.712 | USD 15,899 | - |
| 2026-01-12 | BUY | 296 | 55.749 | 51.610 | 52.024 | USD 15,399 | - |
| 2026-01-09 | BUY | 444 | 56.125 | 53.170 | 53.465 | USD 23,739 | - |
| 2026-01-07 | BUY | 296 | 53.915 | 49.718 | 50.138 | USD 14,841 | - |
| 2026-01-02 | BUY | 148 | 47.049 | 45.510 | 45.664 | USD 6,758 | - |
| 2025-12-30 | BUY | 148 | 48.250 | 47.040 | 47.161 | USD 6,980 | - |
| 2025-12-23 | SELL | -1,776 | 49.400 | 48.605 | 48.684 | USD -86,464 | - |
| 2025-12-19 | SELL | -5,065 | 49.000 | 45.065 | 45.458 | USD -230,247 | - |
| 2025-12-17 | SELL | -795 | 49.040 | 47.610 | 47.753 | USD -37,964 | - |
| 2025-12-16 | SELL | -159 | 50.190 | 48.380 | 48.561 | USD -7,721 | - |
| 2025-12-15 | BUY | 318 | 50.930 | 49.280 | 49.445 | USD 15,724 | - |
| 2025-12-11 | BUY | 1,265 | 50.075 | 48.190 | 48.378 | USD 61,199 | - |
| 2025-12-04 | BUY | 3,140 | 48.620 | 46.630 | 46.829 | USD 147,043 | - |
| 2025-12-02 | BUY | 2,355 | 46.040 | 44.595 | 44.740 | USD 105,362 | - |
| 2025-11-28 | BUY | 157 | 46.820 | 45.000 | 45.182 | USD 7,094 | - |
| 2025-11-26 | BUY | 471 | 46.400 | 44.500 | 44.690 | USD 21,049 | - |
| 2025-11-26 | BUY | 471 | 46.400 | 44.500 | 44.690 | USD 21,049 | - |
| 2025-11-25 | BUY | 785 | 45.040 | 43.070 | 43.267 | USD 33,965 | - |
| 2025-11-24 | BUY | 157 | 44.863 | 43.090 | 43.267 | USD 6,793 | - |
| 2025-11-20 | SELL | -628 | 45.155 | 41.720 | 42.064 | USD -26,416 | - |
| 2025-11-19 | BUY | 157 | 43.565 | 42.170 | 42.309 | USD 6,643 | - |
| 2025-11-18 | BUY | 942 | 43.975 | 42.280 | 42.449 | USD 39,987 | - |
| 2025-11-17 | BUY | 314 | 44.360 | 41.962 | 42.202 | USD 13,251 | - |
| 2025-11-14 | BUY | 157 | 43.947 | 40.975 | 41.272 | USD 6,480 | - |
| 2025-11-12 | BUY | 157 | 43.480 | 42.050 | 42.193 | USD 6,624 | - |
| 2025-11-10 | BUY | 156 | 41.560 | 39.890 | 40.057 | USD 6,249 | - |
| 2025-11-06 | BUY | 156 | 43.890 | 42.380 | 42.531 | USD 6,635 | - |
| 2025-11-04 | BUY | 157 | 42.780 | 41.510 | 41.637 | USD 6,537 | - |
| 2025-10-30 | BUY | 785 | 44.695 | 42.350 | 42.585 | USD 33,429 | - |
| 2025-10-29 | BUY | 314 | 42.900 | 43.855 | 43.759 | USD 13,740 | - |
| 2025-10-22 | SELL | -628 | 40.430 | 42.720 | 42.491 | USD -26,684 | - |
| 2025-10-20 | BUY | 314 | 42.450 | 42.810 | 42.774 | USD 13,431 | - |
| 2025-10-17 | BUY | 784 | 41.570 | 42.795 | 42.672 | USD 33,455 | - |
| 2025-10-15 | BUY | 1,248 | 44.150 | 45.960 | 45.779 | USD 57,132 | - |
| 2025-10-03 | BUY | 1,085 | 40.860 | 42.010 | 41.895 | USD 45,456 | - |
| 2025-10-02 | BUY | 155 | 41.510 | 42.177 | 42.110 | USD 6,527 | - |
| 2025-09-30 | BUY | 310 | 41.650 | 43.480 | 43.297 | USD 13,422 | - |
| 2025-09-29 | BUY | 310 | 43.510 | 47.410 | 47.020 | USD 14,576 | - |
| 2025-09-25 | BUY | 310 | 35.890 | 36.871 | 36.773 | USD 11,400 | - |
| 2025-09-24 | SELL | -2,644 | 35.180 | 36.310 | 36.197 | USD -95,705 | - |
| 2025-09-18 | BUY | 163 | 35.480 | 35.745 | 35.718 | USD 5,822 | - |
| 2025-09-17 | BUY | 489 | 34.200 | 35.090 | 35.001 | USD 17,115 | - |
| 2025-08-20 | SELL | -652 | 29.090 | 29.640 | 29.585 | USD -19,289 | - |
| 2025-07-30 | BUY | 652 | 29.230 | 30.150 | 30.058 | USD 19,598 | - |
| 2025-07-17 | SELL | -326 | 33.020 | 33.280 | 33.254 | USD -10,841 | - |
| 2025-07-16 | BUY | 840 | 31.900 | 32.670 | 32.593 | USD 27,378 | - |
| 2025-07-11 | SELL | -1,280 | 31.930 | 32.210 | 32.182 | USD -41,193 | - |
| 2025-07-07 | BUY | 480 | 29.060 | 30.343 | 30.215 | USD 14,503 | - |
| 2025-07-02 | BUY | 8,800 | 29.440 | 30.010 | 29.953 | USD 263,586 | - |
| 2025-06-20 | BUY | 1,661 | 30.160 | 30.860 | 30.790 | USD 51,142 | - |
| 2025-06-11 | BUY | 310 | 32.330 | 33.350 | 33.248 | USD 10,307 | - |
| 2025-06-10 | BUY | 310 | 33.080 | 33.770 | 33.701 | USD 10,447 | - |
| 2025-06-04 | SELL | -155 | 32.130 | 32.650 | 32.598 | USD -5,053 | - |
| 2025-04-23 | BUY | 155 | 32.370 | 32.890 | 32.838 | USD 5,090 | - |
| 2025-04-10 | SELL | -1,240 | 26.850 | 27.170 | 27.138 | USD -33,651 | - |
| 2025-04-08 | SELL | -155 | 25.560 | 27.273 | 27.102 | USD -4,201 | - |
| 2025-04-07 | SELL | -155 | 26.380 | 27.230 | 27.145 | USD -4,207 | - |
| 2025-04-04 | SELL | -775 | 26.890 | 28.535 | 28.370 | USD -21,987 | - |
| 2025-04-01 | BUY | 1,356 | 30.620 | 33.420 | 33.140 | USD 44,938 | - |
| 2025-03-31 | SELL | -459 | 33.540 | 34.545 | 34.444 | USD -15,810 | - |
| 2025-03-21 | BUY | 2,150 | 34.420 | 35.290 | 35.203 | USD 75,686 | - |
| 2025-03-14 | SELL | -2,336 | 34.470 | 35.630 | 35.514 | USD -82,961 | - |
| 2025-03-07 | SELL | -292 | 33.280 | 34.145 | 34.059 | USD -9,945 | - |
| 2025-03-04 | SELL | -146 | 34.060 | 34.750 | 34.681 | USD -5,063 | - |
| 2025-02-25 | BUY | 292 | 32.300 | 34.795 | 34.545 | USD 10,087 | - |
| 2025-02-19 | SELL | -145 | 36.600 | 36.740 | 36.726 | USD -5,325 | - |
| 2025-02-13 | BUY | 435 | 35.260 | 35.850 | 35.791 | USD 15,569 | - |
| 2025-02-12 | BUY | 145 | 35.210 | 35.220 | 35.219 | USD 5,107 | - |
| 2025-02-11 | BUY | 580 | 34.930 | 36.660 | 36.487 | USD 21,162 | - |
| 2024-12-30 | BUY | 1,667 | 50.670 | 51.280 | 51.219 | USD 85,382 | - |
| 2024-11-18 | SELL | -2,055 | 53.700 | 55.050 | 54.915 | USD -112,850 | - |
| 2024-11-08 | SELL | -137 | 60.690 | 60.930 | 60.906 | USD -8,344 | - |
| 2024-10-21 | SELL | -137 | 58.700 | 58.880 | 58.862 | USD -8,064 | - |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of CRNX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 291,811 | 10 | 422,190 | 69.1% |
| 2025-09-18 | 255,311 | 4,887 | 441,317 | 57.9% |
| 2025-09-17 | 188,956 | 0 | 259,138 | 72.9% |
| 2025-09-16 | 203,554 | 46 | 341,724 | 59.6% |
| 2025-09-15 | 274,635 | 30 | 448,716 | 61.2% |
| 2025-09-12 | 212,918 | 4 | 332,544 | 64.0% |
| 2025-09-11 | 387,813 | 4,439 | 687,673 | 56.4% |
| 2025-09-10 | 271,583 | 180 | 472,484 | 57.5% |
| 2025-09-09 | 435,551 | 10,514 | 645,587 | 67.5% |
| 2025-09-08 | 321,931 | 100 | 446,007 | 72.2% |
| 2025-09-05 | 341,734 | 5,833 | 547,129 | 62.5% |
| 2025-09-04 | 381,128 | 0 | 505,163 | 75.4% |
| 2025-09-03 | 545,896 | 3,603 | 690,216 | 79.1% |
| 2025-09-02 | 320,458 | 1,530 | 581,108 | 55.1% |
| 2025-08-29 | 302,502 | 0 | 582,657 | 51.9% |
| 2025-08-28 | 200,718 | 0 | 302,611 | 66.3% |
| 2025-08-27 | 102,469 | 343 | 177,212 | 57.8% |
| 2025-08-26 | 112,474 | 0 | 194,567 | 57.8% |
| 2025-08-25 | 165,204 | 0 | 263,113 | 62.8% |
| 2025-08-22 | 187,758 | 3,090 | 538,677 | 34.9% |
| 2025-08-21 | 185,854 | 1,565 | 714,284 | 26.0% |
| 2025-08-20 | 88,347 | 12 | 180,947 | 48.8% |
| 2025-08-19 | 127,062 | 1,989 | 256,813 | 49.5% |
| 2025-08-18 | 98,462 | 0 | 154,915 | 63.6% |
| 2025-08-15 | 272,245 | 2,909 | 364,113 | 74.8% |
| 2025-08-14 | 195,415 | 5,120 | 386,307 | 50.6% |
| 2025-08-13 | 180,925 | 108 | 441,798 | 41.0% |
| 2025-08-12 | 123,251 | 0 | 304,481 | 40.5% |
| 2025-08-11 | 254,714 | 1,686 | 471,534 | 54.0% |
| 2025-08-08 | 427,524 | 71 | 845,094 | 50.6% |
| 2025-08-07 | 232,990 | 0 | 429,931 | 54.2% |
| 2025-08-06 | 245,049 | 453 | 455,360 | 53.8% |
| 2025-08-05 | 201,437 | 1,908 | 582,449 | 34.6% |
| 2025-08-04 | 105,804 | 12 | 271,833 | 38.9% |
| 2025-08-01 | 189,908 | 631 | 307,789 | 61.7% |
| 2025-07-31 | 156,522 | 0 | 272,309 | 57.5% |
| 2025-07-30 | 177,608 | 0 | 284,862 | 62.3% |
| 2025-07-29 | 186,650 | 1,295 | 330,974 | 56.4% |
| 2025-07-28 | 135,934 | 800 | 165,427 | 82.2% |
| 2025-07-25 | 170,240 | 173 | 313,564 | 54.3% |
| 2025-07-24 | 100,554 | 82 | 184,823 | 54.4% |
| 2025-07-23 | 119,806 | 200 | 158,505 | 75.6% |
| 2025-07-22 | 102,666 | 226 | 190,447 | 53.9% |
| 2025-07-21 | 154,005 | 0 | 288,631 | 53.4% |
| 2025-07-18 | 184,879 | 1,777 | 371,360 | 49.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy